This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Oct 1;25(28):4505-6.

doi: 10.1200/JCO.2007.13.1011.

Barriers to effective TRAIL-targeted therapy of malignancy

Martin J S Dyer, Marion MacFarlane, Gerald M Cohen

PMID: 17906217
DOI: 10.1200/JCO.2007.13.1011

Comment

Barriers to effective TRAIL-targeted therapy of malignancy

Martin J S Dyer et al. J Clin Oncol. 2007.

. 2007 Oct 1;25(28):4505-6.

doi: 10.1200/JCO.2007.13.1011.

Authors

Martin J S Dyer, Marion MacFarlane, Gerald M Cohen

PMID: 17906217
DOI: 10.1200/JCO.2007.13.1011

No abstract available

PubMed Disclaimer

Comment on

On the TRAIL toward death receptor-based cancer therapeutics.
Gajewski TF. Gajewski TF. J Clin Oncol. 2007 Apr 10;25(11):1305-7. doi: 10.1200/JCO.2006.09.9804. J Clin Oncol. 2007. PMID: 17416849 No abstract available.
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB. Tolcher AW, et al. J Clin Oncol. 2007 Apr 10;25(11):1390-5. doi: 10.1200/JCO.2006.08.8898. J Clin Oncol. 2007. PMID: 17416859 Clinical Trial.

Similar articles

TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. Mahalingam D, et al. Cancer Treat Rev. 2009 May;35(3):280-8. doi: 10.1016/j.ctrv.2008.11.006. Epub 2008 Dec 30. Cancer Treat Rev. 2009. PMID: 19117685 Review.
TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.
Gasparini C, Vecchi Brumatti L, Monasta L, Zauli G. Gasparini C, et al. Curr Med Chem. 2013;20(17):2254-71. doi: 10.2174/0929867311320170009. Curr Med Chem. 2013. PMID: 23458616 Review.
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Amm HM, et al. Cancer Biol Ther. 2011 Mar 1;11(5):431-49. doi: 10.4161/cbt.11.5.14671. Epub 2011 Mar 1. Cancer Biol Ther. 2011. PMID: 21263219 Free PMC article. Review.
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS. Abdulghani J, et al. PLoS One. 2013 Sep 26;8(9):e75414. doi: 10.1371/journal.pone.0075414. eCollection 2013. PLoS One. 2013. PMID: 24086526 Free PMC article.
TRAIL-receptor antibodies as a potential cancer treatment.
Buchsbaum DJ, Forero-Torres A, LoBuglio AF. Buchsbaum DJ, et al. Future Oncol. 2007 Aug;3(4):405-9. doi: 10.2217/14796694.3.4.405. Future Oncol. 2007. PMID: 17661715 Review.

See all similar articles

Cited by

Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects.
Berindan-Neagoe I, Braicu C, Irimie A. Berindan-Neagoe I, et al. Int J Nanomedicine. 2012;7:6035-47. doi: 10.2147/IJN.S36523. Epub 2012 Dec 12. Int J Nanomedicine. 2012. PMID: 23251091 Free PMC article.
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.
Picarda G, Trichet V, Téletchéa S, Heymann D, Rédini F. Picarda G, et al. Am J Cancer Res. 2012;2(1):45-64. Epub 2011 Oct 9. Am J Cancer Res. 2012. PMID: 22206045 Free PMC article.
Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
Di X, Zhang G, Zhang Y, Takeda K, Rivera Rosado LA, Zhang B. Di X, et al. Oncotarget. 2013 Sep;4(9):1349-64. doi: 10.18632/oncotarget.1174. Oncotarget. 2013. PMID: 23988408 Free PMC article.
Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers.
Miyata Y, Mukae Y, Harada J, Matsuda T, Mitsunari K, Matsuo T, Ohba K, Sakai H. Miyata Y, et al. Molecules. 2020 Nov 11;25(22):5252. doi: 10.3390/molecules25225252. Molecules. 2020. PMID: 33187225 Free PMC article. Review.
Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways.
van Dijk M, Halpin-McCormick A, Sessler T, Samali A, Szegezdi E. van Dijk M, et al. Cell Death Dis. 2013 Jul 4;4(7):e702. doi: 10.1038/cddis.2013.214. Cell Death Dis. 2013. PMID: 23828565 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information